Epigenetic Reprogramming and the Longevity Bottleneck: Why the Science Is Ahead of the Pathway

• Epigenetics governs gene expression without altering the DNA sequence. What ages is not the code, but which genes are switched on.
• Partial cell reprogramming demonstrably lowers the epigenetic age of cells, yet the window between rejuvenation and tumorigenesis is narrow.
• Epigenetic markers can be read as clocks. Their reliability varies sharply, none is FDA-cleared, and what methylation age actually measures is not fully understood.
• The bottleneck is not the science. Aging is not a recognized regulatory indication, and the trial designed to change that has been stalled for a decade.
• Our position: the measurement layer sits closer to patients than the rejuvenation layer, and it is currently underpriced.

What are epigenetic changes, and why do they matter?

Epigenetic changes are modifications to the way DNA is packaged, marked, and read. They alter gene activity without touching the genetic code beneath.

The core idea is compact. Every one of your cells carries the same DNA. What shifts as you age is not the code but which genes are expressed, and epigenetics is the control layer that governs that switch.

This is why different cells with identical genomes become radically different things. Muscle cells, immune system cells, and neurons all read the same library, and epigenetic mechanisms determine which books lie open. A muscle cell keeps its contractile genes accessible, silences the other genes that would define other cells, and holds that arrangement for decades. The developmental biologist Conrad Waddington gave the field its lasting metaphor in the 1950s: an epigenetic landscape, a sloping terrain down which a cell rolls until it settles into one valley, one identity, among the many once available to it.

The most persuasive demonstration of epigenetic regulation in humans is not a laboratory result at all. Identical twins share a DNA sequence, yet monozygotic twins diverge across a lifetime in health conditions, disease onset, and appearance. A substantial part of that divergence is epigenetic. Environmental factors, exposures, and behavior leave marks the genome alone cannot account for.

How far those marks travel is a separate and unresolved question. Epigenetic tags are sometimes described as inherited across generations, shaping traits and disease susceptibility in children who never encountered the original exposure. In plants and several animal models the evidence for such epigenetic inheritance is strong. In humans it remains contested; evolutionary biologists continue to debate it, because disentangling genuine epigenetic inheritance from shared environment and genetic confounding is extraordinarily difficult. For now, claims about inherited epigenetic marks in people belong in the column of hypotheses rather than established findings.

What makes any of this investable rather than merely interesting is one property: epigenetic marks are modifiable. The genome is fixed at conception. The epigenome is written and rewritten across a lifetime, which turns it into a drug target rather than a constraint.

How gene expression is controlled without altering the DNA sequence

Gene expression is controlled by chemical marks and structural packaging that render certain genes physically reachable by the transcription machinery while keeping other genes sequestered.

Three epigenetic mechanisms do most of the work, and they operate in concert rather than in sequence. DNA methylation attaches methyl groups directly to the DNA molecule. Histone modifications alter the histone proteins that DNA wraps around. Chromatin remodeling physically repositions the entire DNA-and-histone complex.

Gene regulation is the sum of the three. A gene is not simply on or off; it is more or less reachable. Epigenetic modifications adjust that reachability, and the resulting pattern - the epigenetic profile of a cell - is what makes a liver cell a liver cell and not a neuron.

DNA methylation: methyl groups, CpG sites, and methylation patterns

DNA methylation adds methyl groups to cytosine bases at CpG sites, which generally blocks transcription and silences the associated gene.

The mechanism is mechanical. Methyl groups attached to cytosine physically obstruct RNA polymerase from binding a gene's promoter, and transcription never initiates. Methylation marks accumulate and shift across a lifetime, and the link between aging and DNA methylation levels has been recognised since the late 1960s, as Horvath and Raj document in Nature Reviews Genetics.

Two enzyme families warrant attention from anyone evaluating this space.

DNMT1 maintains DNA methylation patterns through DNA replication. When a cell divides, the newly synthesised strand starts blank, and DNMT1 copies the pattern from the parent strand onto the daughter. Without it, epigenetic information would dissolve at every division. This is why methylation produces heritable changes in the cellular sense: the marks survive DNA replication and pass to daughter cells, even though the DNA sequence beneath them never changed.

Ten eleven translocation enzymes, the TET dioxygenases, do the opposite. They drive active DNA demethylation, stripping marks rather than preserving them. This is no technicality. Age reversal through cellular reprogramming depends on active demethylation, not on marks passively fading.

Aberrant methylation ranks among the best-characterised epigenetic alterations in both aging and disease. In cancer cells, tumour suppressor genes are frequently silenced by hypermethylation of their promoters. The gene remains intact; it is simply rendered unreadable.

Histone modifications: acetylation, methylation, and the histone proteins

Histone modifications are chemical changes to the proteins DNA wraps around, and they dictate how tightly that DNA is packed.

Histone acetylation generally promotes transcriptional activation, because acetyl groups loosen the grip between histones and DNA and expose the region for transcription. Histone methylation is more ambiguous: depending on which residue carries the mark, it can activate or repress. Epigenetic marks are therefore not merely off-switches. The code is combinatorial, and reading it requires knowing both the mark and its address.

Chromatin remodeling and nucleosome positioning

Chromatin remodeling repositions nucleosomes to regulate whether the transcription machinery can physically reach a gene.

A nucleosome is the basic packaging unit - DNA wound around a histone core. Where those nucleosomes sit relative to a promoter determines access. Slide one over a binding site and the gene falls quiet regardless of its methylation status. Nucleosome positioning is increasingly read as an aging signal in its own right, and newer clocks are being built on the histone code, chromatin accessibility, and nucleosome positioning rather than on methylation alone.

What is epigenetic reprogramming?

Epigenetic reprogramming is the deliberate resetting of a cell's epigenetic marks toward a different state - usually younger or more plastic - without editing the DNA sequence.

The term covers two very different operations, and conflating them is the most common error in the field.

Full reprogramming erases cellular identity, converting somatic cells into induced pluripotent stem cells. Partial reprogramming resets age-associated marks while leaving identity intact. The first is a tool for regenerative medicine; the second is the therapeutic thesis of the entire longevity industry. They share a mechanism and little else.

The Yamanaka factors: four defined factors that reset cell fate

The Yamanaka factors are four defined factors - OCT4, SOX2, KLF4, and c-MYC - that can revert adult cells to a pluripotent state resembling embryonic stem cells.

In 2006, Takahashi and Yamanaka showed that expressing these four transcription factors reprograms the developmental potential of adult cells, allowing them to be converted into various cell types. The work founded the field of cell reprogramming and earned a Nobel Prize. Through the 2000s, a run of publications established that the identity of many different cell types, across species, could be erased to produce induced pluripotent stem cells.

The collective abbreviation, OSKM factors, carries less information than its subsets. OSK is the same set minus c-MYC, the most oncogenic of the four, and it is the combination behind much of the age-reversal work. The omission is deliberate: it lowers cancer risk.

Reprogramming is not instantaneous. It proceeds through recognised stages - from initiation, through a maturation phase, to stabilisation - and the epigenetic remodeling that resets cell fate is progressive rather than binary. That gradualism is what makes partial reprogramming conceptually possible. You can stop partway.

Reprogramming factors and the risk of full reprogramming

Reprogramming factors carry a fundamental liability: pushed too far, they erase what the cell is and produce tumours.

Full reprogramming poses genuine oncogenic risk. Cells lose identity and function, and continuous expression of OSKM in adult mice invariably leads to cancer, as Abad and colleagues showed in 2013 and Ohnishi and colleagues confirmed in 2014. The early attempts were unforgiving; mice died within two days of expressing OSKM.

Transient induction is not clean either. Seven days of OSKM expression followed by withdrawal can initiate dysplastic changes, with neoplasms developing within two to three weeks in the pancreas, liver, and kidney. The plain fact underlying every serious program is that these cells can develop cancer.

The insight that opened the therapeutic field was to stop early: expose cells to the reprogramming factors long enough to reset aging-related expression, but not long enough to erase what the cell is. Whether that window existed at all was an open question, because rejuvenation and dedifferentiation might have proved inseparable.

They are not. Olova and colleagues, writing in Aging Cell in 2019, found that partial reprogramming produces a steady decline in epigenetic age before the loss of somatic identity. Age falls first; identity goes later. That ordering is the foundation of the therapeutic field, and everything downstream depends on it.

It carries a cost that easy summaries tend to omit. Transient reprogramming temporarily represses somatic cell identity rather than leaving it untouched, and screens across every combination of the Yamanaka factor set have found that no single factor is responsible for the effect. Cyclic induction and targeted delivery are the mitigation strategies under investigation, not settled solutions.

Cyclic expression of OSKM factors is also frequently reported to extend lifespan in mice. The foundational result, from Ocampo and colleagues, used a progeroid mouse model carrying mutant lamin A - the protein responsible for Hutchinson-Gilford progeria syndrome. Extending lifespan in a premature-aging model is a real and important finding, but it is not equivalent to extending lifespan in normally aging mice, and that distinction is easily lost when the result is compressed.

Epigenetic reprogramming during embryonic development

Natural epigenetic reprogramming occurs during early embryonic development, after fertilisation, when the epigenome is largely wiped and rewritten.

This matters because it establishes that the process is no artefact of the laboratory. Normal development already includes large-scale erasure and re-establishment of epigenetic marks. It is the mechanism by which a fertilised egg - carrying the epigenetic profiles of two adult gametes - produces embryonic stem cells capable of becoming every tissue in the body.

The therapeutic bet is that this natural capacity can be borrowed and throttled: invoke a fraction of the process that embryonic development runs to completion, then halt before cell fate is lost.

Epigenetic alterations in aging: drift, methylation, and the epigenetic landscape

Aging drives progressive epigenetic drift - a gradual, patterned degradation of epigenetic information across multiple tissues.

Mammals undergo predictable epigenetic changes with age, including alterations to DNA methylation patterns that serve as age clocks. What drives those changes has not been established. Epigenetic alterations in aging include aberrant DNA methylation, in which some regions gain marks and others lose them, and the epigenetic landscape grows noisier. Cells drift away from the crisp epigenetic signatures of their youth toward a blurred version of their own identity.

DNA damage repair and the loss of epigenetic information

One leading hypothesis holds that aging is caused by epigenetic information lost during DNA damage repair rather than by mutations to the genetic code.

This is the information theory of aging, and it produced one of the field's most striking experiments. A research team at Harvard Medical School, led by David Sinclair, built a mouse system called ICE - inducible changes to the epigenome - to test whether epigenetic change causes aging or merely accompanies it.

The design is elegant. The team created temporary, fast-healing double strand breaks in mouse DNA, mimicking the low-grade breaks mammalian cells sustain daily from breathing, sunlight, and chemical exposure. Crucially, the breaks were placed outside coding regions, so no mutations were introduced; any aging that followed could therefore be attributed to epigenetic disruption alone.

The mice aged - physiologically, cognitively, and molecularly, including an advancement of the epigenetic clock. The proposed mechanism is the relocalisation of chromatin modifiers hypothesis: double strand breaks pull chromatin-modifying proteins away from their posts to sites of repair, and epigenetic information is lost when they fail to return. Aging, on this account, is a filing error accumulated by the DNA damage repair system.

Published in Cell in 2023 after thirteen years of work, the study reported that a breakdown in epigenetic information drives aging in mice independently of changes to the genetic code, and that restoring epigenome integrity reverses those signs. Commentary from the National Institute on Aging called the causal claim provocative and worth further study - the appropriate posture for a mouse result and a working hypothesis rather than established human biology.

The focus on double strand breaks is not arbitrary. They occur at a rate of 10 to 50 per cell per day, and a comparison across 18 rodent species found that of all DNA repair processes, DSB repair correlated most strongly with lifespan.

Can we reverse aging, or only slow it?

In cells, aging can be reversed. In organisms it cannot yet, and that distinction is where most public discussion goes astray.

The cellular evidence is real. In a 2020 study, ectopic induction of OSK in mouse retinal ganglion cells restored youthful DNA methylation patterns, transcript profiles, and tissue function without erasing cellular identity - an effect that required active DNA demethylation. Damaged optic nerves survived and regrew toward the brain. Partial reprogramming can improve tissue function and regenerative capacity in aged animals.

What has not happened is equally clear. No reprogramming medicine has completed a human trial, and no epigenetic therapy for aging has been approved anywhere. Ongoing research is still working to identify aging biomarkers reliable enough to judge whether an intervention worked at all - which turns out to be the actual constraint on the field.

Epigenetic therapies are not hypothetical in general, and this is the nuance most coverage misses. Epigenetic drugs targeting the enzymes involved in DNA methylation and histone modification are already approved and in clinical use, most prominently in blood cancers, where hypomethylating agents treat myelodysplastic syndromes and acute myeloid leukaemia. Successful targeted epigenetic therapies can reverse the silencing of tumour suppressor genes in cancer cells. The principle that you can drug the epigenome is settled. Whether you can drug it to reverse aging is not.

Chemical cocktails: reprogramming without genetic manipulation

Chemical cocktails are combinations of small molecules that can induce partial reprogramming without introducing genes - avoiding viral delivery, though not the safety question.

Delivery is the practical obstacle to reprogramming at scale. Delivery systems for reprogramming factors face real technical difficulty: viral vectors, mRNA, peptides, and nanoformulations each carry immune, stability, or uptake problems, and non-integrative delivery has become a major research priority. Chemical induction sidesteps the problem entirely, if it works.

In 2023, a Harvard Medical School research team published a screen for small molecules that rejuvenate human cells without altering the genome. They identified six chemical cocktails, each containing five to seven small molecules, which within a week restored a youthful genome-wide transcript profile and reversed transcriptomic age in human fibroblasts - including cells from a 94-year-old donor and from a patient with progeria - without compromising cellular identity or producing iPSC-like states. A separate line of work found that a cocktail of only two small molecules restored multiple aging phenotypes in aged human fibroblasts and extended both lifespan and healthspan in C. elegans.

That result is easily compressed into the claim that chemical cocktails induce epigenetic reprogramming safely - but the paper argues the opposite. Its authors write that, given the toxic effects of expressing all four Yamanaka factors in mice, the safety of chemical rejuvenation cocktails must be tested rigorously in mammalian animal models before human trials begin. Reversing transcriptomic age in a dish is not a safety finding. Chemical reprogramming removes the genetic manipulation; it does not remove the tumorigenicity question.

Epigenetic therapy was also widely forecast to transform precision medicine by 2025. That date has passed. No epigenetic reprogramming therapy reached clinical practice by 2025, and none has since.

Epigenetic markers and the clocks that read them

Epigenetic markers can be assembled into clocks that estimate age from methylation patterns. They are research biomarkers, not cleared diagnostics.

The method reads age-related epigenetic modifications, most often the accumulation of methyl groups at CpG sites. Three generations exist, and the distinction matters more than most accounts acknowledge.

First-generation clocks were trained to predict chronological age. The first multi-tissue estimator, published by Steve Horvath in Genome Biology in 2013, used 353 CpG sites and took over four years of collecting public methylation data to build. Second-generation clocks moved past birthdays to model health phenotypes and mortality risk. Third-generation clocks were trained on differences in the rate of multi-organ deterioration between people of the same chronological age.

Horvath's 2013 clock is routinely credited with estimating biological age, but it does not. It was trained to predict chronological age, and its accuracy was measured against birthdays. The clocks that estimate biological age in the sense people usually mean - mortality risk and pace of decline - are the second- and third-generation models built later, several of them also by Horvath. Treating the 2013 clock as a biological-age tool collapses fifteen years of methodological development into a single misleading phrase.

The caveats that follow are load-bearing.

Reliability varies enormously between clocks. Cross-platform reliability puts the third-generation pace-of-aging clock at r = 0.94 and the leading second-generation mortality clock at r = 0.91, but the original multi-tissue clock at r = 0.65 and the second-generation phenotypic clock at r = 0.58. In practice, some widely cited clocks return inconsistent results between laboratories.

None is cleared. Epigenetic clocks remain investigational biomarkers, with no FDA clearance for clinical decision-making.

The training data is narrow. Most clocks were built predominantly on Caucasian populations, and accuracy may be reduced in other groups. Tissue choice matters too. Horvath has noted that applying a blood-trained clock to saliva without correction produces substantial error, and that without linkage to clinical outcomes there is no way to validate whether a clock predicts anything meaningful at all. Transient events - recent illness, surgery, or acute stress - move the reading.

Beneath all of it sits an admission the field has not resolved: it is not yet known what exactly DNA methylation age measures.

That is not grounds to dismiss the tools. It is precisely why they are the most important unsolved problem in the category. Before anything can be rejuvenated it has to be measured, and the measurement has to be trusted well enough for a regulator to accept it. Monitoring reprogramming efficacy requires reliable biomarkers. The biomarker is a precondition for the therapy - and a product in its own right.

Why aging itself became an investment target

The thesis is that a single mechanism sits beneath many age-related diseases, so one intervention could return value across all of them.

That reframe - targeting the process that produces the diseases of aging rather than treating them one at a time - moved longevity from fringe interest to a financeable category. Capital followed. In June 2026, a preclinical longevity biotech raised USD 435 million at a USD 3.1 billion post-money valuation with no product, no revenue, and no human trial yet run. Venture capital is accelerating the development of epigenetic startups, and strategies in epigenetic therapy now target tissue damage from disease, aging, and environmental exposure across a widening set of indications: metabolic disorders through restored gene expression, neurodegenerative disease including Alzheimer's and Parkinson's, and oncology.

The category-level numbers are less dramatic and more useful. Longevity biotech recorded roughly USD 5.72 billion across about 170 deals in 2025, and USD 3.74 billion across 49 financing events in the first quarter of 2026 alone - 56% ahead of the same quarter a year earlier, according to analysis by Longevity.Technology using PitchBook data.

The distribution tells a different story from the headline. The same analysis puts the average round at USD 91.2 million and the median at USD 21.8 million. A gap that wide means a handful of outsized transactions are dragging the mean upward, and the typical longevity company raises a fraction of what the headlines imply. Aggregate capital is not accessible capital.

The bottleneck in longevity biotech is not the science

The constraint is regulatory. Aging is not an approved indication, so no drug can be developed or marketed to treat it.

Drugs are approved for specific indications. Because aging has never been designated as one, no clear regulatory path exists for a drug that targets it, and the frameworks lag well behind the innovation. This is not an abstraction; it explains the shape of every serious program in the field, because reprogramming companies file against a named organ disease - liver, kidney, or vasculature. The science may target the process. The filing must target a condition.

The evidence that this is structural rather than temporary is the trial designed to fix it. In 2015, Nir Barzilai at the Albert Einstein College of Medicine designed a study of 3,000 adults aged 65 to 79 over six years, with a composite primary endpoint linking stroke, heart failure, dementia, myocardial infarction, cancer, and death. The composite was negotiated with the FDA precisely because the traditional single-disease format does not fit a drug claiming to delay several diseases at once. The point was never the drug. The point was to establish aging as an indication.

As of 2026, it has not enrolled a single participant, because pharmaceutical companies will not fund it.

The circularity is explicit. Industry cannot justify the cost of a large longevity trial without a regulatory pathway, and the pathway will not exist until someone runs the trial. The endpoint problem loops back on itself as well, because proving that a therapy slows aging requires an accepted way to measure aging - and the clocks are not cleared for that job.

Clinical applications of epigenetic reprogramming remain largely experimental, with early-stage trials only now beginning. The challenges are consistently named by the people doing the work: tumorigenicity risk, delivery difficulty, and regulatory hurdles. Combination therapies may improve efficacy. Non-integrative delivery may solve the vector problem. Neither addresses the absence of a pathway.

So the science is advancing, the capital is arriving, the pathway is absent, the endpoints are contested, and the measurement is unvalidated. The bottleneck is not in the laboratory.

There is an ethical layer here too. Epigenetic determinism - the idea that your marks are your destiny - raises real concerns about personal autonomy, particularly when biological age scores are sold to consumers as verdicts rather than estimates. And if these therapies work, equitable access stops being a rhetorical concern and becomes a practical one. A medicine that adds healthy years, priced beyond the population that needs it, widens exactly the gap it claims to close.

Where epigenetics meets early screening

The lesson epigenetics teaches - that aging leaves an objective, measurable signal before symptoms appear - is the same principle behind the diagnostics we back.

Aegis Capital does not hold an epigenetics company. What we hold is the thesis underneath it: a measurable signal that precedes the symptom, with a regulatory route that exists today.

Inoko Vision, a company in our current portfolio, is building NeuroFET, a non-invasive optical device that reads eye micro-movements during visual tasks as an objective biomarker of neurological state. The reasoning is anatomical: the eye is the most externally accessible part of the central nervous system, and specific brain regions govern eye movement, so neurological change registers almost immediately in movement dynamics. The company is developing and validating the technology for early screening of neurodegenerative disease. Preliminary results in Alzheimer's patients show a substantial difference from healthy age-matched controls, and studies confirming early-diagnostic capability are ongoing.

Approxima, also in our current portfolio, is developing a percutaneous right-ventricular remodeling system for tricuspid regurgitation. Its relevance here is not incidental. Tricuspid regurgitation is a pathology of the aging society: it affects over 13 million patients worldwide, carries a 50% two-year mortality rate in severe untreated cases, and nearly 99% of patients are denied open-heart surgery because the mortality risk is too high, per Topilsky and colleagues (2019) and Nath and colleagues (2004). It is aging biology with a defined regulatory pathway - the combination the field needs and rarely achieves.

Both companies do what the epigenetics field is trying to do. They turn a process of aging into an objective, measurable, actionable signal. The difference is that they can file.

The Aegis Capital perspective on epigenetics and longevity

Our thesis is that the measurement and diagnostics layer of longevity sits closer to patients than the rejuvenation layer, and that it is currently underpriced.

The data cuts both ways. Diagnostics and biological-age companies hold roughly 2.78% of disclosed longevity capital, according to New Market Pitch's 2026 analysis, despite measuring the thing the entire category depends on. Preventive health platforms attract the largest checks because they look scalable. One reading is that investors have correctly judged that diagnostics cannot capture downstream value. Our reading is that this is mispricing, and that a field which cannot yet validate its own endpoints will eventually pay for the tools that can.

Geography sharpens the point. Over the twelve months to May 2026, North America captured 96.74% of disclosed longevity capital, while Europe appears through a single disclosed round representing 1.23%. The same analysis notes that longevity does not yet behave like a standard allocation category for generalist portfolios. It behaves like a specialist-conviction market, where investors back specific theses rather than buying broad exposure. That is the market we were built for.

We are equally clear about scale. Epigenetic reprogramming programs run on hundreds of millions of dollars. We invest up to PLN 3 million initially and up to PLN 8 million per company across the fund's lifecycle, from a PLN 80 million fund backed by 22 private investors, targeting up to 16 companies with at least 75% in HealthTech. We are not going to fund a liver-rejuvenation program, and we see no reason to imply otherwise. We fund the tools, biomarkers, and diagnostics the category runs on - the layer where a fund our size changes outcomes rather than rounds.

Longevity and Diagnostics sit among our five focus areas, alongside AI and Digital Health, Nutritech, and Digital Therapy and Mental Health. We invest in early-stage companies across Central and Eastern Europe and support their entry into international markets. Beyond capital, founders receive regulatory-pathway guidance, go-to-market support, and introductions to clinicians, hospitals, and pharma partners - all part of the partnership rather than a separate fee. Our team has backed over 20 companies, including 14 in HealthTech.

If you are building in this space, reach us at aegis@aegiscap.vc.

Frequently Asked Questions

What is epigenetics in simple terms?

Epigenetics refers to the control layer over your genes. Every cell holds the same DNA, but not every gene is switched on in every cell, or at every age. Epigenetic marks - chemical tags on DNA and on the histone proteins around it - decide which genes get used. Aging changes those marks, not the underlying code.

Can epigenetic changes be reversed?

In cells, yes. Partial reprogramming lowers the epigenetic age of cells before they lose somatic identity, as Olova and colleagues reported in Aging Cell in 2019, and chemical cocktails have reversed transcriptomic age in human fibroblasts within a week. In humans it remains unproven. No reprogramming medicine has completed a human trial, and laboratory reversal is not clinical benefit.

What is the difference between biological age and chronological age?

Chronological age is time since birth, and it is fixed. Biological age is an estimate of your body's condition relative to that number, and it is modifiable. The critical caveat is that biological age is an estimate rather than a measurement, and different epigenetic clocks give different answers from the same sample.

Are epigenetic clocks accurate?

It depends entirely on the clock. Cross-platform reliability ranges from r = 0.94 for the leading pace-of-aging clock down to r = 0.58 for a widely used second-generation clock, which means some return inconsistent results between laboratories. No epigenetic clock has FDA clearance for clinical decision-making, and what methylation age measures is not fully established.

Is epigenetic reprogramming safe?

Not yet established. Full reprogramming carries substantial teratoma and tumour risk, and continuous expression of the Yamanaka factors in adult mice invariably produces cancer. Even transient induction has generated neoplasms in animal models within weeks. Partial, cyclic, targeted, and chemical approaches are the mitigation strategies under active investigation, not settled solutions.

What is the difference between full and partial reprogramming?

Full reprogramming converts somatic cells into induced pluripotent stem cells and erases cell identity, which is useful for regenerative medicine and dangerous in a living body. Partial reprogramming stops early, resetting age-associated epigenetic marks while the cell remains itself. The therapeutic longevity field rests entirely on the second.

How close is epigenetic medicine to patients?

The first human trial of a cell-reprogramming medicine is expected to begin in 2027, targeting a specific liver condition rather than aging itself, because aging is not an approvable indication. Reprogramming for aging is pre-clinical today. Epigenetic drugs of a different kind are already approved and used in blood cancers.

Does Aegis Capital invest in longevity startups?

Yes. Longevity is one of our five focus areas, alongside AI and Digital Health, Diagnostics, Nutritech, and Digital Therapy and Mental Health. We invest up to PLN 3 million initially, with follow-on potential up to PLN 8 million per company, in early-stage companies across Central and Eastern Europe. Our current focus within longevity is the measurement and diagnostics layer rather than therapeutics.

‍